Linagliptin-related pancreatitis in a diabetic patient with biliary calculus A case report

Basit Öğe Kaydı
dc.contributor.authorSevencan, Nurhayat Ozkan
dc.contributor.authorOzkan, Aysegul Ertinmaz
dc.contributor.authorKayhan, Burcak
dc.date.accessioned2024-09-29T16:03:12Z
dc.date.available2024-09-29T16:03:12Z
dc.date.issued2018
dc.departmentKarabük Üniversitesien_US
dc.description.abstractRationale: Dipeptidyl peptidase-4 inhibitors are commonly used drugs for the treatment of type 2 diabetes mellitus. While acute pancreatitis cases induced by saxagliptin, sitagliptin, and vildagliptin (all of which are members of the dipeptidyl peptidase-4 group) have been reported, there is no clear evidence suggesting that linagliptin may cause pancreatitis, and information in this regard is limited to a few studies. Moreover, no pancreatitis cases have been reported that were directly associated with linagliptin. Patient concerns: We present a case of linagliptin-related pancreatitis in a 79-year-old male diabetic patient with biliary calculi. The patient, who was diagnosed with acute pancreatitis 4 months after initiating linagliptin 5mg/d treatment, was admitted to our hospital. Diagnoses: The patient's pancreatic enzymes were high. Ultrasonography showed multiple biliary calculi, and abdominal computed tomography showed edematous pancreatitis. Interventions: Linagliptin was discontinued and clinical improvement was achieved with standard acute pancreatitis treatment. Outcomes: This is the 1st case report suggesting that linagliptin might be associated with the risk of pancreatitis and could be an etiologic cause of pancreatitis, similar to the other members of its group. Lessons: While the results of previous studies stated that there was no data to prove a causal relationship between dipeptidyl peptidase-4 inhibitors and pancreatitis, concerns regarding this subject have continued to arise. Therefore, new and comprehensive studies are needed to determine the long-term effects of dipeptidyl peptidase-4 inhibitors on type 2 diabetes mellitus patients and to shed light on the side effects of these medications.en_US
dc.identifier.doi10.1097/MD.0000000000013284
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.issue50en_US
dc.identifier.pmid30557974en_US
dc.identifier.scopus2-s2.0-85058760808en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1097/MD.0000000000013284
dc.identifier.urihttps://hdl.handle.net/20.500.14619/5941
dc.identifier.volume97en_US
dc.identifier.wosWOS:000456326400014en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofMedicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectbiliary calculusen_US
dc.subjectdipeptidyl peptidase-4 inhibitorsen_US
dc.subjectlinagliptinen_US
dc.subjectpancreatitisen_US
dc.subjecttype 2 diabetes mellitusen_US
dc.titleLinagliptin-related pancreatitis in a diabetic patient with biliary calculus A case reporten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu